A Phase 4 interventional study of Device programming in Heart Failure, sponsored by Montreal Heart Institute. Completed at 11 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-08.
Sponsored by Montreal Heart Institute · Phase 4, Interventional, and Treatment
Heart failure is a major health problem in Canada. Recent advances in medical and device therapy have helped to reduce the morbidity and mortality of patients with this problem. Among these treatments, cardiac resynchronization therapy (CRT) has very recently been shown to be effective to improve functional class, quality of life and exercise tolerance of the patients with the most severe symptoms of heart failure and a prolonged duration of the QRS on the 12-lead Electrocardiography (ECG).
Resynchronization of the failing ventricle is currently achieved by pacing the left and right ventricles simultaneously with specialized electrodes and a cardiac stimulator. However, controversy persists concerning the optimal configuration for cardiac pacing in these patients. Right ventricular pacing alone has been shown to be deleterious in some patient populations. The benefits of biventricular pacing in heart failure patients may be due primarily to left ventricular stimulation and may, in some patients, be decreased by the presence of simultaneous RV stimulation. Preliminary data from our own animal work suggest that in the majority of cases, LV stimulation alone is better than RV stimulation, and that BiV stimulation represents an intermediary situation between LV and RV stimulation.
5,697 studies on the registry are indexed under Heart Failure; 1,219 are open to participants now.
This study's planned enrollment of 120 is above the median of 72 across 3,733 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Montreal Heart Institute is the lead sponsor of 101 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient must answer "yes"
Exclusion Criteria:
Patient must have answered "NO" to all of the exclusion criteria
Does the patient have:
left univentricular pacing
Device: Device programming
biventricular pacing
Device: Device programming
6-month period
The primary endpoint is total exercise duration at a constant submaximal load (ETT submaximal load is defined as 75% of peak exercise during the baseline metabolic evaluation)
Time frame: one year
Clinical, electrical, echocardiographic, MUGA scan endpoints, Neuro-hormones
Time frame: one year
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Montreal Heart Institute